RNTX (Rein Therapeutics) E10: $-49.36 (As of Mar. 2026)


RNTX Rein Therapeutics Inc RNTX
30 GF Score
Price $0.97
! 1 Warning Sign
View Full Analysis

What is Rein Therapeutics E10?

Rein Therapeutics RNTX +3.71% 30 E10 is $-49.36 as of Mar. 2026. GuruFocus rates RNTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Rein Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.190. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-49.36 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-26), Rein Therapeutics's current stock price is $0.9707. Rein Therapeutics's E10 for the quarter that ended in Mar. 2026 was $-49.36. Rein Therapeutics's Shiller PE Ratio of today is .


Rein Therapeutics  (NAS:RNTX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Rein Therapeutics E10 Related Terms


Rein Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Rein Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rein Therapeutics E10 Chart

Rein Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -49.41

Rein Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -50.66 -49.41 -49.36

RNTX vs ATRA, OSTX, IBIO: E10 Comparison

For the Biotechnology subindustry, Rein Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rein Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rein Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Rein Therapeutics's Shiller PE Ratio falls into.


RNTX
30GF Score
Rein Therapeutics Inc RNTX
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rein Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rein Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.19/330.2130*330.2130
=-0.190

Current CPI (Mar. 2026) = 330.2130.

Rein Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 -10.176 241.018 -13.942
201609 -7.771 241.428 -10.629
201612 -8.173 241.432 -11.178
201703 -6.223 243.801 -8.429
201706 -219.600 244.955 -296.033
201709 -9.000 246.819 -12.041
201712 -9.325 246.524 -12.491
201803 -10.400 249.554 -13.761
201806 -12.800 251.989 -16.773
201809 -10.000 252.439 -13.081
201812 -9.600 251.233 -12.618
201903 -9.800 254.202 -12.730
201906 -5.200 256.143 -6.704
201909 -5.600 256.759 -7.202
201912 -5.000 256.974 -6.425
202003 -4.800 258.115 -6.141
202006 -2.800 257.797 -3.587
202009 -2.600 260.280 -3.299
202012 -2.400 260.474 -3.043
202103 -1.600 264.877 -1.995
202106 -1.200 271.696 -1.458
202109 -1.400 274.310 -1.685
202112 -1.490 278.802 -1.765
202203 -1.860 287.504 -2.136
202206 -1.760 296.311 -1.961
202209 -1.400 296.808 -1.558
202212 -1.000 296.797 -1.113
202303 -1.050 301.836 -1.149
202306 -0.390 305.109 -0.422
202309 -0.400 307.789 -0.429
202312 -1.570 306.746 -1.690
202403 -0.860 312.332 -0.909
202406 -0.450 314.175 -0.473
202409 -0.270 315.301 -0.283
202412 -2.200 315.605 -2.302
202503 -0.250 319.799 -0.258
202506 -0.280 322.561 -0.287
202509 -0.210 324.800 -0.213
202512 -1.220 324.054 -1.243
202603 -0.190 330.213 -0.190

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-49.36 mean?
Rein Therapeutics (RNTX) has a E10 of $-49.36 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Rein Therapeutics and its competitors.
Is Rein Therapeutics' E10 too high?
Rein Therapeutics' current E10 is $-49.36. Overall, Rein Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rein Therapeutics' E10 compare to ATRA and OSTX?
Rein Therapeutics' E10 of $-49.36 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Rein Therapeutics and its competitors. Rein Therapeutics's current E10 is $-49.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rein Therapeutics stock overvalued right now?
Rein Therapeutics (RNTX) has a current E10 of $-49.36. The current E10 is $-49.36. Rein Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Rein Therapeutics (RNTX), the current E10 is $-49.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rein Therapeutics Business Description

Address 12407 North Mopac Expressway, Suite 250, No.390, Austin, TX, USA, 78758
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
30GF Score

Get the complete analysis for RNTX

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.97
Price